Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company, ImmunoGen
So what: Trastuzumab emtansine, previously known as T-DM1, is an experimental drug targeting patients with metastatic HER2-positive breast cancer. In phase three results released very early this morning, the Roche and ImmunoGen drug was shown to significantly extend patients' lives when compared to GlaxoSmithKline's
Now what: ImmunoGen's Targeted Antibody Payload technology has the potential to be the cornerstone combination drug of the future, and the success of trastuzumab emtansine is a key part of that. Aside from Seattle Genetics
Craving more input? Start by adding ImmunoGen to you free and personalized Watchlist so you can keep up on the latest news with the company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
Motley Fool newsletter services have recommended buying shares of ImmunoGen. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.